Stock analysts at StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical device company’s stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.
Get Our Latest Research Report on Avinger
Avinger Trading Up 4.1 %
Avinger (NASDAQ:AVGR – Get Free Report) last issued its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The business had revenue of $1.91 million for the quarter, compared to analyst estimates of $2.52 million. As a group, sell-side analysts forecast that Avinger will post -2.08 earnings per share for the current year.
About Avinger
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Featured Stories
- Five stocks we like better than Avinger
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Hasbro’s Management Made All the Right Calls This Quarter
- Golden Cross Stocks: Pattern, Examples and Charts
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Transportation Stocks Investing
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.